SCHEMBL3562552

SCHEMBL3562552

CCOC(=O)C(=CNCc1ccccc1)C(=O)c1cccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.48
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 1/20 0.46
CA12 O43570 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
CDC25A P30304 1/20 0.45
CDC25C P30307 1/20 0.45
MAPT P10636 2/20 0.45
GAA P10253 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
PPID Q08752 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
DHODH Q02127 2/20 0.44
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP2D6 P10635 1/20 0.43
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562547 1.00 CDC25B (0.48) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL3565370 0.90 ALDH1A1 (0.46) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL3565366 0.90 ALDH1A1 (0.46) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL3559984 0.88 KDM4E (0.52) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL3559986 0.88 KDM4E (0.52) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL3557961 0.87 KDM4E (0.48) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL3557963 0.87 KDM4E (0.48) CDC25BALDH1A1KDM4ECA12CA2
SCHEMBL10861896 0.85 MAPT (0.60) ALDH1A1KDM4EMAPTGAATDP1
SCHEMBL15955781 0.84 MAPT (0.46) ALDH1A1KDM4EMAPTGAATDP1
SCHEMBL15962311 0.84 MAPT (0.46) ALDH1A1KDM4EMAPTGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof OXFORD FINANCE CORPORATION 2008-03-13 US claimed
JP-2007536262-A 2007-12-13 JP claimed
EP-1742904-A4 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF UNIV CALIFORNIA (US) 2007-04-18 EP claimed
EP-1742904-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-17 EP claimed
WO-2005108347-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-11-17 WO claimed
US-7825278-B2 Substituted enaminones, their derivatives and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-11-02 US disclosed
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof OXFORD FINANCE CORPORATION 2008-03-13 US disclosed
EP-1742904-A4 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF UNIV CALIFORNIA (US) 2007-04-18 EP disclosed
EP-1742904-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-17 EP disclosed
WO-2005108347-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof GABRB2, GABRB1, GABRB3 CDC25B 4622/4885ALDH1A1 423/4885KDM4E 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.